2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.11 Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor

P2.11A.11 Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor

Back to course

Pdf Summary

The study investigates the impact of proton pump inhibitor (PPI) use on the fecal microbiome in patients with non-small cell lung cancer (NSCLC) undergoing treatment with immune checkpoint inhibitors (ICIs). Recent data suggest that medications like PPIs can impact immune-related adverse events (irAEs) and the gut microbiome. The aim was to study microbiome taxonomic and functional features correlated with PPI use and the development of irAEs in NSCLC patients treated with ICIs.<br /><br />In this research, stool samples from patients with stage III and IV NSCLC treated with ICIs were collected and analyzed for microbiome profiles using metagenomics methodologies. The study found that PPI use was associated with both the development of irAEs and alterations in the gut microbiome. Of the patients studied, half experienced irAEs, with the most common being skin, liver, endocrine, and pulmonary toxicities. Notably, 58% of the patients were on PPIs, and about two-thirds of these developed irAEs, suggesting a potential correlation between PPI use and adverse immune responses.<br /><br />The research highlighted a specific increase in the relative abundance of the bacterium Collinsella in patients with irAEs, which was further augmented with PPI use. This suggests a relationship between PPI use, microbiome dysbiosis, and immune-related side effects in this patient population.<br /><br />The conclusion calls for further, larger studies with longitudinal sampling to better understand the impact of PPI use on outcomes for NSCLC patients undergoing ICI therapy. The study emphasizes the need to consider medication history, such as PPI use, when assessing potential side effects and treatment outcomes in cancer therapies. Acknowledgements extend to patients, families, and administrative supporters involved in the study.

Asset Subtitle

Yiqing Huang

Meta Tag

Speaker Yiqing Huang

Topic Metastatic NSCLC – Immunotherapy

Keywords

proton pump inhibitor

fecal microbiome

non-small cell lung cancer

immune checkpoint inhibitors

immune-related adverse events

microbiome dysbiosis

Collinsella

metagenomics

gut microbiome

cancer therapy